RIKEN BioResource Research center has entered into a licensing agreement with Thermo Fisher, Inc. (formerly Invitrogen IP Holdings, Inc.) in July 2009 regarding the preservation and distribution of bioresources utilizing Gateway^® Technology covered by patents owned by Thermo Fisher, Inc. According to the agreement, for the distribution of Gateway^® expression clones containing mammalian cDNA, users are required to bear a licensing fee equivalent amount.

BRC has recently conducted a review prompted by recent exchange rate fluctuations and other factors, and as a result, BRC has decided to revise the licensing fee equivalent amount as follows. We kindly ask for your understanding in this matter.

BRC will continue to strive towards enhancing the availability and quality of bioresources, aiming to contribute to the advancement of research activities for all users. We look forward to your continued active utilization.

Best Regards,
Director, Toshihiko Shiroishi, Ph.D.
RIKEN BioResource Research Center

For bioreagents requested after April 1, 2024 (Monday) Japan Time, BRC will provide them at the revised fees. For requests made before this date, the current fees will apply.

For further details, please contact the following Division:

• Gene Engineering Division (Email: dnabank.brc@riken.jp)